Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer

BACKGROUND: The DNA-damage immune-response (DDIR) signature is an immune-driven gene expression signature retrospectively validated as predicting response to anthracycline-based therapy. This feasibility study prospectively evaluates the use of this assay to predict neoadjuvant chemotherapy response...

Descripción completa

Detalles Bibliográficos
Autores principales: Parkes, Eileen E., Savage, Kienan I., Lioe, Tong, Boyd, Clinton, Halliday, Sophia, Walker, Steven M., Lowry, Keith, Knight, Laura, Buckley, Niamh E., Grogan, Andrena, Logan, Gemma E., Clayton, Alison, Hurwitz, Jane, Kirk, Stephen J., Xu, Jiamei, Sidi, Fatima Abdullahi, Humphries, Matthew P., Bingham, Victoria, James, Jaqueline A., James, Colin R., Paul Harkin, D., Kennedy, Richard D., McIntosh, Stuart A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770594/
https://www.ncbi.nlm.nih.gov/pubmed/34728791
http://dx.doi.org/10.1038/s41416-021-01599-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770594/
https://www.ncbi.nlm.nih.gov/pubmed/34728791
http://dx.doi.org/10.1038/s41416-021-01599-0

Ejemplares similares